Zydus Lifesciences Extends Winning Streak with USFDA Approval

As on 26 Nov 2025,

posted its third straight positive close, ending the session with a 1.3% gain. The stock’s momentum was supported by the pharma company securing final USFDA approval for Verapamil Hydrochloride extended-release tablets in 120 mg, 180 mg, and 240 mg strengths. The medication, used for managing high blood pressure, recorded annual US sales of $24.5 million as per IQVIA MAT September 2025. The approval boosted sentiment, aiding the stock’s steady upward trend. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.